A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid to Investigate Safety and Efficacy of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma

Trial ID # NCT02659384; EORTC-1508
Phase II
Drug Class Angiogenesis Inhibitors: VEGF
Drug Name Bevacizumab
Alternate Drug Names immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin
Drugs in Trial Acetylsalicylic acid, Atezolizumab, Bevacizumab
Eligible Participant

Platinum resistant ovarian cancer

Patients Enrolled

122; 70% w/ prior bevacizumab

Therapy Setting


Study Design

Double Blind, Randomized


ORR, PFS, TFST, evaluated per RECIST


Bev vs Bev+Ate vs Bev+Ate+Asa:

ORR: 24.1 vs 20.7 vs 27.6%
PFS: 2.3 vs 4.1 vs 4.0 months
TFST: 3.0 vs 5.3* vs 5.8 months*

Clinically Significant Adverse Events

Bev vs Bev+Ate vs Bev+Ate+Asa:
Serious AE:
Grade 3-4 AE: overall (48 vs 32 vs 30%)


The addition of atezolizumab to bevacizumab (with or without acetylsalicylic acid) improves PFS and TFST


Banerjee S et al. Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma. Annals Oncol (2021) 32 (suppl_5): abstract LBA32

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.